Delcath Systems Inc (DCTH) Stock Analysis

Delcath Systems Inc (DCTH) is a publicly traded company in the HEALTHCARE sector. It trades at $10.53, carries a market capitalization of $372.14M, a price-to-earnings ratio of 1078.00. This page summarizes the public market data, fundamentals, and frequently asked questions for DCTH, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - MEDICAL DEVICES

Exchange: NASDAQ

Key Metrics

Market Sentiment

Delcath Systems Inc currently has a Bullish sentiment score of 0.23.

About Delcath Systems Inc

Delcath Systems, Inc. is a pioneering interventional oncology company focused on transforming treatment paradigms for patients suffering from primary and metastatic liver cancers in the U.S. and Europe. Headquartered in New York, the firm utilizes its proprietary technologies to facilitate targeted delivery of cancer therapies directly to the liver, optimizing therapeutic efficacy while reducing systemic toxicity. With a robust pipeline of clinical programs and a commitment to expanding its m...

GNG Research Analysis

GNG Research scores Delcath Systems Inc (DCTH) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for DCTH.

Frequently Asked Questions

Does DCTH pay dividends?

Delcath Systems Inc (DCTH) does not currently pay a regular dividend.

What is DCTH's P/E ratio?

Delcath Systems Inc has a price-to-earnings (P/E) ratio of 1078.00.

What is DCTH's market cap?

Delcath Systems Inc (DCTH) has a market capitalization of $372.14M with a current stock price of $10.53.